### BEFORE THE MEDICAL BOARD OF CALIFORNIA DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:	)	
GARY SCOTT RINZLER, M.D.	)	Case No. 02-2011-218274
Physician's and Surgeon's	)	
Certificate No. G 67994	)	
Respondent	)	
	)	

#### **DECISION AND ORDER**

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on September 19, 2014.

IT IS SO ORDERED: August 21, 2014.

MEDICAL BOARD OF CALIFORNIA

French Ow MD

Dev Gnanadev, M.D., Chair

Panel B

1	Kamala D. Harris	
2	Attorney General of California THOMAS S. LAZAR	
3	Supervising Deputy Attorney General JANNSEN TAN	
4	Deputy Attorney General State Bar No. 237826	
5	1300 I Street, Suite 125 P.O. Box 944255	
	Sacramento, CA 94244-2550	
6	Telephone: (916) 445-3496 Facsimile: (916) 327-2247	
7	Attorneys for Complainant	
8		
9		
10	BEFORE T MEDICAL BOARD OF	
11	DEPARTMENT OF CONSTATE OF CAL	SUMER AFFAIRS
12	STATE OF CALL	IFORMA
13		
14	In the Matter of the Accusation Against:	Case No. 02-2011-218274
15	GARY SCOTT RINZLER, M.D.	STIPULATED SETTLEMENT AND
16	3701 J Street, Suite 207 Sacramento, CA 95816	DISCIPLINARY ORDER
17	Physician's and Surgeon's Certificate No. G 67994	
18	Respondent.	
19		
20		
21	IT IS HEREBY STIPULATED AND AGREEI	D by and between the parties to the above-
22	entitled proceedings that the following matters are tru	ie:
23	PARTIE	<u>S</u>
24	Kimberly Kirchmeyer ("Complainant") is	s the Executive Director of the Medical
25	Board of California. She brought this action solely in	n her official capacity and is represented in
26	this matter by Kamala D. Harris, Attorney General of	f the State of California, by Jannsen Tan,
27	Deputy Attorney General.	
28		
<b></b>	1	

- 2. Respondent Gary Scott Rinzler, M.D. ("Respondent") is represented in this proceeding by Stephen Michael Boreman, Esq., Slote, Links & Boreman, LLP, whose address is 815 Morningside Drive, Folsom, CA 95630.
- 3. On or about February 5, 1990, the Medical Board of California issued Physician's and Surgeon's Certificate No. G 67994 to Gary Scott Rinzler, M.D. (Respondent). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought in Accusation No. 02-2011-218274 and will expire on May 31, 2015, unless renewed.

#### **JURISDICTION**

4. On August 27, 2013, Complainant, Kimberly Kirchmeyer, in her then official capacity as the Interim Executive Director of the Board, filed Accusation No. 02-2011-218274 against Respondent. On August 27, 2013, Respondent was served with a true and correct copy of Accusation No. 02-2011-218274, together with true and correct copies of all other statutorily required documents, at his address of record on file with the Board which was and is: 3701 J Street, Suite 207, Sacramento, CA 95816. A true and correct copy of Accusation No. 02-2011-218274 is attached hereto as Exhibit "A" and incorporated by reference as if fully set forth herein. On or about September 12, 2013, Respondent filed a Notice of Defense and requested a hearing on the charges and allegations contained in Accusation No. 02-2011-218274.

#### **ADVISEMENT AND WAIVERS**

- 5. Respondent has carefully read, fully discussed with counsel, and fully understands the charges and allegations in Accusation No. 02-2011-218274. Respondent has also carefully read, fully discussed with counsel, and fully understands the effects of this Stipulated Settlement and Disciplinary Order.
- 6. Respondent is fully aware of his legal rights in this matter, including the right to a hearing on the charges and allegations in Accusation No. 02-2011-218274; the right to confront and cross-examine the witnesses against him; the right to present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision;

and all other rights accorded by the California Administrative Procedure Act, the California Code of Civil Procedure and other applicable laws, having been fully advised of same by his attorney of record, Stephen Michael Boreman, Esq.

7. Respondent, having the benefit of counsel, hereby voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

#### **CULPABILITY**

- 8. Respondent does not contest that, at an administrative hearing, Complainant could establish a *prima facie* case with respect to the charges and allegations contained in Accusation No. 02-2011-218274, a true and correct copy of which is attached hereto as Exhibit "A", and that he has thereby subjected his Physician's and Surgeon's Certificate No. G 67994 to disciplinary action.
- 9. Respondent agrees that if he ever petitions for early termination or modification of probation, or if an accusation and/or petition to revoke probation is filed against him, before the Medical Board of California, all of the charges and allegations contained in Accusation No. 02-2011-218274 shall be deemed true, correct and fully admitted by Respondent for purposes of that proceeding or any other licensing proceeding involving Respondent in the State of California.
- 10. Respondent agrees that his Physician's and Surgeon's Certificate No. G 67994 is subject to discipline and he agrees to be bound by the Board's imposition of discipline as set forth in the Disciplinary Order below.

#### **CONTINGENCY**

- 11. The parties agree that this Stipulated Settlement and Disciplinary Order shall be submitted to the Board for its consideration in the above-entitled matter and, further, that the Board shall have a reasonable period of time in which to consider and act on this Stipulated Settlement and Disciplinary Order after receiving it. By signing this stipulation, Respondent fully understands and agrees that he may not withdraw his agreement or seek to rescind this stipulation prior to the time that the Board considers and acts upon it.
- 12. The parties agree that this Stipulated Settlement and Disciplinary Order shall be null and void and not binding upon the parties unless approved and adopted by the Board, except

for this paragraph, which shall remain in full force and effect. Respondent fully understands and agrees that in deciding whether or not to approve and adopt this Stipulated Settlement and Disciplinary Order, the Board may receive oral and written communications from its staff and/or the Attorney General's office. Communications pursuant to this paragraph shall not disqualify the Board, any member thereof, and/or any other person from future participation in this or any other matter affecting or involving Respondent. In the event that the Board, in its discretion, does not approve and adopt this Stipulated Settlement and Disciplinary Order, with the exception of this paragraph, it shall not become effective, shall be of no evidentiary value whatsoever, and shall not be relied upon or introduced in any disciplinary action by either party hereto. Respondent further agrees that should the Board reject this Stipulated Settlement and Disciplinary Order for any reason, Respondent will assert no claim that the Board, or any member thereof, was prejudiced by its/his/her review, discussion and/or consideration of this Stipulated Settlement and Disciplinary Order or of any matter or matters related hereto.

#### **ADDITIONAL PROVISIONS**

- 13. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to be an integrated writing representing the complete, final and exclusive embodiment of the agreements of the parties in the above-entitled matter.
- 14. The parties agree that copies of this Stipulated Settlement and Disciplinary Order, including copies of the signatures of the parties, may be used in lieu of original documents and signatures and, further, that such copies shall have the same force and effect as originals.
- 15. In consideration of the foregoing admissions and stipulations, the parties agree the Board may, without further notice to or opportunity to be heard by Respondent, issue and enter the following Disciplinary Order:

#### **DISCIPLINARY ORDER**

IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. G 67994 issued to Respondent Gary Scott Rinzler, M.D. (Respondent) is revoked. However, the revocation is stayed and Respondent is placed on probation for five (5) years from the effective date of this decision on the following terms and conditions.

1. <u>CONTROLLED SUBSTANCES- MAINTAIN RECORDS AND ACCESS TO</u>

RECORDS AND INVENTORIES. Respondent shall maintain a record of all controlled substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any recommendation or approval which enables a patient or patient's primary caregiver to possess or cultivate marijuana for the personal medical purposes of the patient within the meaning of Health and Safety Code section 11362.5, during probation, showing all the following: 1) the name and address of patient; 2) the date; 3) the character and quantity of controlled substances involved; and 4) the indications and diagnosis for which the controlled substances were furnished.

Respondent shall keep these records in a separate file or ledger, in chronological order. All records and any inventories of controlled substances shall be available for immediate inspection and copying on the premises by the Board or its designee at all times during business hours and shall be retained for the entire term of probation.

- 2. <u>EDUCATION COURSE</u>. Within 60 calendar days of the effective date of this Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee for its prior approval educational program(s) or course(s) which shall not be less than 40 hours per year, for each year of probation. The educational program(s) or course(s) shall be aimed at correcting any areas of deficient practice or knowledge and shall be Category I certified. The educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure. Following the completion of each course, the Board or its designee may administer an examination to test Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65 hours of CME of which 40 hours were in satisfaction of this condition.
- 3. PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in prescribing practices equivalent to the Prescribing Practices Course at the Physician Assessment and Clinical Education Program, University of California, San Diego School of Medicine (Program), approved in advance by the Board or its designee. Respondent shall provide the program with any information and documents that the Program may deem pertinent. Respondent shall participate in and successfully complete

///

///

///

///

the classroom component of the course not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully complete any other component of the course within one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

A prescribing practices course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the course would have been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

4. MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective date of this Decision, Respondent shall enroll in a course in medical record keeping equivalent to the Medical Record Keeping Course offered by the Physician Assessment and Clinical Education Program, University of California, San Diego School of Medicine (Program), approved in advance by the Board or its designee. Respondent shall provide the program with any information and documents that the Program may deem pertinent. Respondent shall participate in and successfully complete the classroom component of the course not later than six (6) months after Respondent's initial enrollment. Respondent shall successfully complete any other component of the course within one (1) year of enrollment. The medical record keeping course shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

7

11 12

10

13 14

15 16

17

18 19

20 21

22

24

23

25 26

27

28

A medical record keeping course taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the course would have been approved by the Board or its designee had the course been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the course, or not later than 15 calendar days after the effective date of the Decision, whichever is later.

PROFESSIONALISM PROGRAM (ETHICS COURSE). Within 60 calendar days of 5. the effective date of this Decision, Respondent shall enroll in a professionalism program, that meets the requirements of Title 16, California Code of Regulations (CCR) section 1358. Respondent shall participate in and successfully complete that program. Respondent shall provide any information and documents that the program may deem pertinent. Respondent shall successfully complete the classroom component of the program not later than six (6) months after Respondent's initial enrollment, and the longitudinal component of the program not later than the time specified by the program, but no later than one (1) year after attending the classroom component. The professionalism program shall be at Respondent's expense and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of licensure.

A professionalism program taken after the acts that gave rise to the charges in the Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board or its designee, be accepted towards the fulfillment of this condition if the program would have been approved by the Board or its designee had the program been taken after the effective date of this Decision.

Respondent shall submit a certification of successful completion to the Board or its designee not later than 15 calendar days after successfully completing the program or not later than 15 calendar days after the effective date of the Decision, whichever is later.

NOTIFICATION. Within seven (7) days of the effective date of this Decision, the 6. Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the

///

Chief Executive Officer at every hospital where privileges or membership are extended to Respondent, at any other facility where Respondent engages in the practice of medicine, including all physician and locum tenens registries or other similar agencies, and to the Chief Executive Officer at every insurance carrier which extends malpractice insurance coverage to Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15 calendar days.

This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

- 7. <u>SUPERVISION OF PHYSICIAN ASSISTANTS</u>. During probation, Respondent is prohibited from supervising physician assistants.
- 8. <u>OBEY ALL LAWS</u>. Respondent shall obey all federal, state and local laws, all rules governing the practice of medicine in California and remain in full compliance with any court ordered criminal probation, payments, and other orders.
- 9. <u>QUARTERLY DECLARATIONS</u>. Respondent shall submit quarterly declarations under penalty of perjury on forms provided by the Board, stating whether there has been compliance with all the conditions of probation.

Respondent shall submit quarterly declarations not later than 10 calendar days after the end of the preceding quarter.

#### 10. GENERAL PROBATION REQUIREMENTS.

#### Compliance with Probation Unit

Respondent shall comply with the Board's probation unit and all terms and conditions of this Decision.

#### Address Changes

Respondent shall, at all times, keep the Board informed of Respondent's business and residence addresses, email address (if available), and telephone number. Changes of such addresses shall be immediately communicated in writing to the Board or its designee. Under no circumstances shall a post office box serve as an address of record, except as allowed by Business and Professions Code section 2021(b).

 Place of Practice

Respondent shall not engage in the practice of medicine in Respondent's or patient's place of residence, unless the patient resides in a skilled nursing facility or other similar licensed facility.

#### License Renewal

Respondent shall maintain a current and renewed California physician's and surgeon's license.

#### Travel or Residence Outside California

Respondent shall immediately inform the Board or its designee, in writing, of travel to any areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty (30) calendar days.

In the event Respondent should leave the State of California to reside or to practice Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of departure and return.

- 11. <u>INTERVIEW WITH THE BOARD OR ITS DESIGNEE</u>. Respondent shall be available in person upon request for interviews either at Respondent's place of business or at the probation unit office, with or without prior notice throughout the term of probation.
- 12. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or its designee in writing within 15 calendar days of any periods of non-practice lasting more than 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is defined as any period of time Respondent is not practicing medicine in California as defined in Business and Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct patient care, clinical activity or teaching, or other activity as approved by the Board. All time spent in an intensive training program which has been approved by the Board or its designee shall not be considered non-practice. Practicing medicine in another state of the United States or Federal jurisdiction while on probation with the medical licensing authority of that state or jurisdiction shall not be considered non-practice. A Board-ordered suspension of practice shall not be considered as a period of non-practice.

26.27.

In the event Respondent's period of non-practice while on probation exceeds 18 calendar months, Respondent shall successfully complete a clinical training program that meets the criteria of Condition 18 of the current version of the Board's "Manual of Model Disciplinary Orders and Disciplinary Guidelines" prior to resuming the practice of medicine.

Respondent's period of non-practice while on probation shall not exceed two (2) years. Periods of non-practice will not apply to the reduction of the probationary term.

Periods of non-practice will relieve Respondent of the responsibility to comply with the probationary terms and conditions with the exception of this condition and the following terms and conditions of probation: Obey All Laws; and General Probation Requirements.

- 13. <u>COMPLETION OF PROBATION</u>. Respondent shall comply with all financial obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the completion of probation. Upon successful completion of probation, Respondent's certificate shall be fully restored.
- 14. <u>VIOLATION OF PROBATION</u>. Failure to fully comply with any term or condition of probation is a violation of probation. If Respondent violates probation in any respect, the Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation, or an Interim Suspension Order is filed against Respondent during probation, the Board shall have continuing jurisdiction until the matter is final, and the period of probation shall be extended until the matter is final.
- 15. <u>LICENSE SURRENDER</u>. Following the effective date of this Decision, if
  Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy
  the terms and conditions of probation, Respondent may request to surrender his or her license.
  The Board reserves the right to evaluate Respondent's request and to exercise its discretion in
  determining whether or not to grant the request, or to take any other action deemed appropriate
  and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent
  shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its
  designee and Respondent shall no longer practice medicine. Respondent will no longer be subject

## **ENDORSEMENT** The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California. Respectfully submitted, Dated: KAMALA D. HARRIS Attorney General of California THOMAS S. LAZAR Supervising Deputy Attorney General JANNSEN TAN Deputy Attorney General Attorneys for Complainant SA2013308474 32000311.doc

## Exhibit A

Accusation No. 02-2011-218274

1 2 3 4 5 6 7	Kamala D. Harris Attorney General of California Thomas S. Lazar Supervising Deputy Attorney General Jannsen Tan Deputy Attorney General State Bar No. 237826 1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 445-3496 Facsimile: (916) 327-2247 Attorneys for Complainant	FILED STATE OF CALIFORNIA MEDICAL BOARD OF CALIFORNIA SACRAMENTO August 27 20 13 BY ANALYST
8	BEFORE T MEDICAL BOARD OF	
9	DEPARTMENT OF CONS STATE OF CAL	
10		1
11	In the Matter of the Accusation Against:	Case No. 02-2011-218274
12 13	GARY SCOTT RINZLER, M.D. 3701 J Street, Suite 207 Sacramento, CA 95816	ACCUSATION
14	Physician's and Surgeon's Certificate No. G 67994	
15		
16	Respondent.	
17		
18	Complainant alleges:	
19	PARTIE	S
20	Kimberly Kirchmeyer (Complainant) brit	ngs this Accusation solely in her official
21	capacity as the Interim Executive Director of the Med	dical Board of California.
22	2. On or about February 5, 1990, the Medic	al Board of California issued Physician's and
23	Surgeon's Certificate Number G 67994 to Gary Scott	Rinzler, M.D. (Respondent). The
24	Physician's and Surgeon's Certificate was in full forc	e and effect at all times relevant to the
25	charges brought herein and will expire on May 31, 20	015, unless renewed.
26	///	
27	///	
28	///	
	1	

#### JURISDICTION

- 3. This Accusation is brought before the Medical Board of California (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.
- 4. Section 2227 of the Code provides that a licensee who is found guilty under the Medical Practice Act may have his or her license revoked, suspended for a period not to exceed one year, placed on probation and required to pay the costs of probation monitoring, be publicly reprimanded and ordered to complete relevant educational courses, or have such other action taken in relation to discipline as the Board or an administrative law judge deems proper.
  - 5. Section 2234 of the Code states:

"The [B]oard shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

- "(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the violation of, or conspiring to violate any provision of this chapter [Chapter 5, the Medical Practice Act].
  - "(b) Gross negligence.

...

- 6. Unprofessional conduct under California Business and Professions Code section 2234 is conduct which breaches the rules or ethical code of the medical profession, or conduct which is unbecoming a member in good standing of the medical profession, and which demonstrates an unfitness to practice medicine. (*Shea v. Board of Medical Examiners* (1978) 81 Cal.App.3d 564, 575.)
  - 7. Section 725 of the Code provides:
- "(a) Repeated acts of clearly excessive prescribing, furnishing, dispensing, or administering of drugs or treatment, repeated acts of clearly excessive use of diagnostic procedures, or repeated acts of clearly excessive use of diagnostic or treatment facilities as determined by the standard of the community of licensees is unprofessional conduct for a

Accusation (02-2011-218274)

physician and surgeon, dentist, podiatrist, psychologist, physical therapist, chiropractor,

optometrist, speech-language pathologist, or audiologist."

1

2

2.5

#### Patient M.M.

- 13. Patient M.M. is Respondent's sister-in-law, who became a Kaiser patient on or about January 6, 2009. Respondent prescribed lorazepam<sup>1</sup> and zolpidem<sup>2</sup> for her sleep and muscle pain respectively.
- 14. On or about January 23, 2009, another Kaiser doctor saw M.M. and discontinued her lorazapem 2mg and zolpidem.
- 15. On or about January 30, 2009, Respondent noted that he received a call from M.M. asking that she be put back on lorazepam and zolpidem. Respondent approved her refill for lorazepam and zolpidem and told her that she needed to come in for a complete exam.

  Respondent did not note a treatment plan or sufficient medical indication to prescribe the drugs.
- 16. During the period of March 2009, Respondent reminded M.M. that she needed to come in for a full examination. In addition to lorazepam and zolpidem, Respondent prescribed her hydrocodone/acetaminophen 10/350 at 90.<sup>3</sup> Respondent did not note any treatment plan.
- 17. During the period of April 2009, Respondent prescribed lorazepam, zolpidem and hydrocodone/acetaminophen 10/350 at 90. Respondent did not note any treatment plan.
- 18. On or about April 13, 2009, Respondent noted that M.M. called stating that she is having problems with her refills. She also stated that she overdid it in a marathon and asked for larger quantity of drugs so she did not have to come in frequently for refills. M.M. also told Respondent that she had been on Prozac (Fluoxetine)<sup>4</sup> in the past and wanted to start it again.

<sup>&</sup>lt;sup>1</sup> Lorazepam is a psychotropic drug for the management of anxiety disorders and sedation or for short-term relief of the symptoms of anxiety. It is a schedule IV controlled substance pursuant to Health and Safety Code section 11057 and a dangerous drug pursuant to Section 4022.

<sup>&</sup>lt;sup>2</sup> Zolpidem is a non-benzodiazepene sedative-hypnotice for the short term treatment of insomnia. Zolpidem produces muscle relaxation and anticonvulsant effects only at doses much higher than the hypnotic dose. It is a schedule IV controlled substance pursuant to Health and Safety Code section 11057 and a dangerous drug pursuant to Section 4022.

<sup>&</sup>lt;sup>3</sup> Hydrocodone bitartrate and acetaminophen is a Schedule II controlled substance pursuant to Health and Safety Code section 11055 (b)(1)(I), a dangerous drug pursuant to Section 4022, and is used to treat moderate to severe pain.

<sup>&</sup>lt;sup>4</sup> Prozac is the trade name for fluoxetine hydrochloride, an antidepressant and a dangerous drug within the meaning of Business and Professions Code 4022.

Respondent prescribed hydrocodone/Acetaminophen 10-325 at 180, fluoxetine 20 mg. at 100, lorazepam 2 mg at 60. Respondent did not note any treatment plan.

- 19. During the period of May 2009 to August 2009, Respondent continued to prescribe and refill M.M.'s hydrocodone/acetaminophen 10-325 at 180, fluoxetine 20 mg. at 100, and lorazepam 2 mg at 60. Respondent did not note any treatment plan.
- 20. On or about August 6, 2009, Respondent notes that "Although sizeable doses, she remains without adverse side effects and fully functional at these levels, over several years (even before joining KP apparently?)." Respondent did not note any treatment plan.
- 21. During the period of August 2009 to August 2010, M.M. would ask for refills and early refills using various reasons to justify the early refill. Respondent did not create a treatment plan for patient M.M. consistent with the Board guidelines for the treatment of pain. Respondent did not perform regularly updated appropriate physical exams of patient M.M. to ensure that she was not misusing drugs.
- 22. During the period of November 2010 to December 2011, Respondent prescribed the following controlled substances and dangerous drugs to M.M.:

DATE FILED	LAST NAME	FIRST NAME	DRUG NAME	STRENGTH	QTY	RX#
11/8/2010	Μ.	M.	LORAZEPAM	2 MG	90	4401296
			APAP/ HYDROCODONE			
11/8/2010	M.	M.	BITARTRATE	325 MG - 10 MG	180	4401298
11/8/2010	Μ.	M.	ZOLIPIDEM TARTRATE	10 MG	30	4401297
			APAP/ HYDROCODONE			
11/15/2010	M.	Μ.	BITARTRATE	325 MG - 10 MG	180	PROPERTY OF STREET
11/15/2010	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	190464
11/15/2010	M.	M.	LORAZEPAM	2 MG	90	190465
11/29/2010	M.	M.	LORAZEPAM	2 MG	90	4401404
			APAP/ HYDROCODONE			
11/29/2010	M.	Μ,	BITARTRATE	325 MG - 10 MG	180	4401403
11/29/2010	M.	М,	ZOLIPIDEM TARTRATE	10 M	60	4401405
			APAP/ HYDROCODONE			
12/14/2010	Μ.	Μ.	BITARTRATE	325 MG - 10 MG	180	195252
12/14/2010	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	195254
12/14/2010	M.	M.	LORAZEPAM	2 MG	90	195253
			APAP/ HYDROCODONE			200
12/27/2010	M.	M.	BITARTRATE	325 MG - 10 MG	180	4401536

	12/27/2010	M.	M.	LORAZEPAM	2 MG	90	4401404
	12/27/2010	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	440105
8594278	12/27/2010	M.	M.	LORAZEPAM	2 MG	90	4401404
	12/27/2010	M,	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	4401536
	12/27/2010	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4401405
837	1/10/2011	M.	Μ.	LORAZEPAM	2 MG	90	199410
			\$4100 <b>8.380</b> 88084 \$4100 \$41000	APAP/ HYDROCODONE			
	1/10/2011	М.	M.	BITARTRATE	325 MG - 10 MG	180	199407
	1/10/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	199409
	1/10/2011	N.4	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	199407
283	1/10/2011	M. M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	199409
Sal.	1/10/2011 1/10/2011	м.	M.	LORAZEPAM	2 MG	90	199410
100000	1/24/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4401538
1955	1/24/2011	M.	M.	LORAZEPAM	2 MG	90	4401537
10-11 61.7	1,24,2011			APAP/ HYDROCODONE			
	1/24/2011	М.	М.	BITARTRATE	325 MG - 10 MG	180	4401536
	1/24/2011	M.	M.	LORAZEPAM	2 MG	90	4401537
				APAP/ HYDROCODONE	225 MG 10 MG	100	4401536
	1/24/2011	M.	Μ.	BITARTRATE	325 MG - 10 MG	180 60	4401536 4401538
	1/24/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG 2 MG	90	104171
1886	2/6/2011	M. M.	M. M.	LORAZEPAM ZOLIPIDEM TARTRATE	2 MG	60	204172
90.5 15.68	2/6/2011	IVI.	IVI.	APAP/ HYDROCODONE	10 WG	00	204172
	2/6/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	204170
			1 1111	APAP/ HYDROCODONE			
1.000	2/6/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	204170
	2/6/2011	M.	М.	ZOLIPIDEM TARTRATE	10 MG	60	204172
672467	2/6/2011	M.	M.	LORAZEPAM	2 MG	90	204171
	2/24/2011	M.	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	4401830
120	2/24/2011	М.	Μ.	LORAZEPAM	2 MG	90	4401832
	2/24/2011	A producer participation of the contract of th	M.	ZOLIPIDEM TARTRATE	10 MG	60	4401833
	2/24/2011	Μ.	М.	LORAZEPAM	2 MG	90	4401832
270 4400				APAP/ HYDROCODONE		400	*****
	2/24/2011	Μ.	M.	BITARTRATE	325 MG - 10 MG	180	4401830
1.159	2/24/2011	M.	Μ.	ZOLIPIDEM TARTRATE	10 MG	60	4401833
	3/10/2011	M.	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	204170
Rail.	3/10/2011	APRIL 2000 - 100 KONTO	M.	ZOLIPIDEM TARTRATE	10 MG	60	20417
	3/10/2011	ST THERESESSANCE	M.	LORAZEPAM	2 MG	90	20417
Pict	J/10/2011	2. 1 <b>71</b> 6.00		APAP/ HYDROCODONE			
	3/10/2011	M.	М.	BITARTRATE	325 MG - 10 MG	180	204170

204172	60	10 MG	ZOLIPIDEM TARTRATE	M.	M.	3/10/2011
204171	90	2 MG	LORAZEPAM	M.	Μ.	3/10/2011
4401832	90	2 MG	LORAZEPAM	M.	М.	3/24/2011
4401831	60	10 MG	ZOLIPIDEM TARTRATE	M.	M.	3/24/2011
			APAP/ HYDROCODONE			
4401830	180	325 MG - 10 MG	BITARTRATE	M.	M.	3/24/2011
4401832	90	2 MG	LORAZEPAM	M.	M.	3/24/2011
4401920	100	225 MC 40 MC	APAP/ HYDROCODONE			2/24/224
4401830 4401831	180 60	325 MG - 10 MG 10 MG	BITARTRATE ZOLIPIDEM TARTRATE	M.	M.	3/24/2011
204172	60	10 M	ZOLIPIDEM TARTRATE	M.	M.	3/24/2011
204172	00	TOIM	APAP/ HYDROCODONE	M.	M.	4/11/2011
214849	180	325 MG - 10 MG	BITARTRATE	M.	M.	4/11/2011
204171	90	2 MG	LORAZEPAM	M.	M.	4/11/2011
4401987	90	2 MG	LORAZEPAM	М.	M.	4/23/2011
			APAP/ HYDROCODONE	i pojektirio		
4401986	180	325 MG - 10 MG	BITARTRATE	M.	M.	4/23/2011
4401988	60	10 MG	ZOLIPIDEM TARTRATE	М.	M.	4/23/2011
220210	180	325 MG - 10 MG	APAP/ HYDROCODONE BITARTRATE	M.	Μ,	5/11/2011
220211	90	2 MG	LORAZEPAM	M.	M.	5/11/2011
220212	60	10 MG	ZOLIPIDEM TARTRATE	м.	M.	5/11/2011
4402252	90	2 MG	LORAZEPAM	M.	М.	5/24/2011
			APAP/ HYDROCODONE			
4402251	180	325 MG - 10 MG	BITARTRATE	M.	M.	5/24/2011
4402253	60	10 MG	ZOLIPIDEM TARTRATE	M.	M.	5/24/2011
214849	180	335 MC 10 MC	APAP/ HYDROCODONE		, A.	5/2/2014
220212	60	325 MG - 10 MG 10 MG	BITARTRATE ZOLIPIDEM TARTRATE	М. М.	M. M.	6/2/2011 6/2/2011
220212	90	2 MG	LORAZEPAM	м. М.	s engagniou te sociali de	6/2/2011
	~~		APAP/ HYDROCODONE	IVI.	IVI.	0/2/2011
4402347	180	325 MG - 10 MG	BITARTRATE	М.	M.	6/14/2011
4402349	60	10 MG	ZOLIPIDEM TARTRATE	M.	M.	6/14/2011
4402247	100	225146 40146	APAP/ HYDROCODONE			
4402347 4402349	180 60	325 MG - 10 MG	BITARTRATE	M.	M.	6/14/2011
4402349	90	10 MG 2 MG	ZOLIPIDEM TARTRATE  LORAZEPAM	M.	M.	6/14/2011
4402348	90	2 MG	LORAZEPAM	М. М.	М. М.	6/15/2011
1702570		ZWG	APAP/ HYDROCODONE	IVI,	IVI.	6/15/2011
223945	180	325 MG - 10 MG	BITARTRATE	М.	M.	7/3/2011
223948	60	10 MG	ZOLIPIDEM TARTRATE	M.	M.	7/3/2011
223946	90	2 MG	LORAZEPAM	M.	Μ.	7/3/2011
223948	60	10 MG	ZOLIPIDEM TARTRATE APAP/ HYDROCODONE	M.	М.	7/3/2011
223945	180	325 MG - 10 MG	BITARTRATE	M.	Μ.	7/3/2011

	-10/2024			LODAZEDANA	2.46	90	223946
	7/3/2011	M.	M.	LORAZEPAM	2 MG	90	223940
2	7/26/2011	M.	M.	LORAZEPAM APAP/ HYDROCODONE	2 MG	90	4402548
3	7/26/2011	Μ.	M.	BITARTRATE	325 MG - 10 MG	180	4402549
.	7/26/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
1	7/26/2011	М.	M,	LORAZEPAM	2 MG	90	4402548
5				APAP/ HYDROCODONE			
	7/26/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402549
,	7/26/2011	Μ.	М.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
,	7/26/2011	Μ.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
	7/26/2011	M.	M.	LORAZEPAM	2 MG	90	4402548
				APAP/ HYDROCODONE		400	4.4005.40
	7/26/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402549
	8/15/2011	М.	Μ.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	223945
)	8/15/2011	Μ.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
	<ul> <li>Box 311 (Assessment September 2015)</li> </ul>	Accessories 5	M.	LORAZEPAM	2 MG	90	223946
	8/15/2011	M.	IVI,	APAP/ HYDROCODONE	2 WO		223340
	8/15/2011	М.	M.	BITARTRATE	325 MG - 10 MG	180	223945
	8/15/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
	8/15/2011	М.	M.	LORAZEPAM	2 MG	90	223946
				APAP/ HYDROCODONE			
	8/15/2011	М.	M.	BITARTRATE	325 MG - 10 MG	180	223945
	8/15/2011	M.	M.	LORAZEPAM	2 MG	90	223946
	8/15/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
	8/29/2011	Μ.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
				APAP/ HYDROCODONE			
	8/29/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402549
	8/29/2011	Μ.	M.	LORAZEPAM	2 MG	90	4402548
	8/29/2011	Μ.	M.	LORAZEPAM	2 MG	90	4402548
	0/20/2011			APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	4402549
	8/29/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
İ	8/29/2011	M.	M. M.	LORAZEPAM	2 MG	90	4402548
	8/29/2011 8/29/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402550
	8/29/2011	M.	IVIV	APAP/ HYDROCODONE	LO MIO		
	8/29/2011	Μ.	М.	BITARTRATE	325 MG - 10 MG	180	4402549
	9/21/2011	M.	M.	LORAZEPAM	2MG	90	223946
	<i></i>			APAP/ HYDROCODONE			- ier
	9/21/2011	Μ.	М.	BITARTRATE	325 MG - 10 MG	180	223945
	9/21/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
	AND THE PROPERTY OF THE PROPER		none.	APAP/ HYDROCODONE			
	9/21/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	223945
'	9/21/2011	Μ.	M.	LORAZEPAM	2 MG	90	223946
	9/21/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
- 1	i						

1	9/21/2011	M.	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	223945
_	9/21/2011	M.	M.	LORAZEPAM	2 MG	90	223946
2	9/21/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
3	9/21/2011	M.	M.	LORAZEPAM	2 MG	90	223946
	9/21/2011	М.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
4			5 CL CCCC 41, V/ vd 1, X-150, X1886 CL CL	APAP/ HYDROCODONE			
5	9/21/2011	M.	М.	BITARTRATE	325 MG - 10 MG	180	223945
				APAP/ HYDROCODONE		Area e a santa	100
6	9/21/2011	Μ.	M.	BITARTRATE	325 MG - 10 MG	180	223945
7	9/21/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	223948
/	9/21/2011	Μ.	M.	LORAZEPAM	2 MG	90	223946
8	10/5/2011	М.	Μ.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
				APAP/ HYDROCODONE			
9	10/5/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402697
10	10/5/2011	М.	M,	LORAZEPAM	2 MG	90	4402698
	10/5/2011	M.	M.	LORAZEPAM	2 MG	90	4402698
11				APAP/ HYDROCODONE			4400607
12	10/5/2011	M.	Μ.	BITARTRATE	325 MG - 10 MG	180	4402697
12	10/5/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
13	10/5/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
	10/5/2011	M.	М.	LORAZEPAM	2 MG	90	4402698
14				APAP/ HYDROCODONE	325 MG - 10 MG	180	4402697
15	10/5/2011	М.	Μ.	BITARTRATE		430.00 (770.00 9090734388888	4402696
	10/5/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402030
16	10/5/2011	M.	M.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	4402697
17	10/5/2011	M.	M.	LORAZEPAM	2 MG	90	4402698
1 /	10/5/2011	21 302007	M.	LORAZEPAM	2 MG	90	4402698
18	10/5/2011	M.	IVI.	APAP/ HYDROCODONE	2300	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, 102050
10	10/5/2011	М.	М.	BITARTRATE	325 MG - 10 MG	180	4402697
19	10/5/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
20				APAP/ HYDROCODONE			
	10/20/2011	М.	М.	BITARTRATE	500 MG -5 MG	15	4412658
21				APAP/ HYDROCODONE			
22	10/20/2011	M.	M.	BITARTRATE	500 MG -5 MG	15	4412658
	10/31/2011	M.	Μ.	ZOLIPIDEM TARTRATE	10 MG	60	220212
23	10/31/2011	M.	M.	LORAZEPAM	2 MG	90	247763
24	10/31/2011	М.	М.	APAP/ HYDROCODONE BITARTRATE	325 MG - 10 MG	180	247777
	ROAL SAND OF CORRESPONDED AND ARRESPONDED	oko muzuate:	M.	LORAZEPAM	2 MG	90	247763
25	10/31/2011			ZOLIPIDEM TARTRATE	10 MG	60	220212
26	10/31/2011	M.	M.	APAP/ HYDROCODONE	10 MO	UU	FEUETE
20	10/31/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	247777
27	10/31/2011		M.	ZOLIPIDEM TARTRATE	10 MG	60	220212
20	10/31/2011				eren eta erren eta erren eta		
28							

11							
				APAP/ HYDROCODONE		- 20	24777
1	10/31/2011	Μ.	M.	BITARTRATE	325 MG - 10 MG	180	247777
$_{2}\parallel$	10/31/2011	M.	M.	LORAZEPAM	2 MG	90	247763
				APAP/ HYDROCODONE	ni pita ing	400	440000
3	11/15/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402697
	11/15/2011	M.	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
4	11/15/2011	М.	M.	LORAZEPAM	2 MG	90	4402698
5	11/15/2011	Μ.	Μ.,	ZOLIPIDEM TARTRATE	10 MG	60	4402696
	11/15/2011	M.	M.	LORAZEPAM	2 MG	90	4402698
6				APAP/ HYDROCODONE			
<u>,</u>	11/15/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	4402697
7				APAP/ HYDROCODONE			line and
8	11/15/2011	М.	M,	BITARTRATE	325 MG - 10 MG	180	4402697
	11/15/2011	М.,	M.	ZOLIPIDEM TARTRATE	10 MG	60	4402696
9	11/15/2011	M.	Μ.	LORAZEPAM	2 MG	90	4402698
10	12/12/2011	M.	M.	LORAZEPAM	2 MG	90	254353
10				APAP/ HYDROCODONE			
11	12/12/2011	M.	M.	BITARTRATE	325 MG - 10 MG	180	254352
				APAP/ HYDROCODONE			
12	12/12/2011	М.	M.	BITARTRATE	325 MG - 10 MG	180	254352
13	12/12/2011	M.	M.	LORAZEPAM	2 MG	90	254353
13							
14	23. On	or abo	ut Septem	iber 19, 2012, Responden	t was interviewed by	a Board	
15	Investigator. Re	espond	lent ackno	owledged that he had been	n "lenient" with M.M	I and that	she
16	repeatedly had s	shown	aberrant l	behavior in the form of lo	ost or otherwise misp	laced med	lications

- that Respondent replaced at one to two week intervals over the course of a year.
- Respondent committed gross negligence in his care and treatment of patient M.M. which included, but was not limited to the following:
- Prescribing excessive amounts of hydrocodone bitartrate and acetaminophen, zolpidem and lorazepam to patient M.M.

#### Patient SR

17

18

19

20

21

22

23

24

25

26

27

28

S.R. is Respondent's wife who was a Kaiser patient starting on or about February 5, 2009. Respondent intermittently saw S.R. during the period of February 5, 2009 to September 2010 and prescribed carisoprodol<sup>5</sup> to S.R. for pain due to surgery. S.R. was also treated by

<sup>&</sup>lt;sup>5</sup> Soma is a brand name for carisoprodol, a central-acting oral skeletal muscle relaxant. Soma is a dangerous drug pursuant to Section 4022 and, effective January 12, 2012, was reclassified as a Schedule IV controlled substance pursuant to Health and Safety Code section (continued...)

T/	۱R	G	E.	T !	PI	H	Α	R	N	V	Α	C	"	1
	1 1111												200	

Date Filled	Last Name	First Name	Drug Name	Strength	Qty	RX#
10/18/2010	R.	S.	CARISOPRODOL	350 MG	120	6608581
12/20/2010	R.	S.	CARISOPRODOL	350 MG	120	6610541
1/27/2011	R.	S.	CARISOPRODOL	350 MG	120	6610541
2/21/2011	R.	S.	CARISOPRODOL	350 MG	120	6612334
3/25/2011	R.	S.	CARISOPRODOL	350 MG	120	6613313
4/22/2011	R.	S.	CARISOPRODOL	350 MG	120	6613313
5/17/2011	R.	S.	CARISOPRODOL	350 MG	120	6613313
6/21/2011	R.	S.	CARISOPRODOL	350 MG	120	6616046
7/18/2011	R.	S.	CARISOPRODOL	350 MG	120	6616800
8/14/2011	R.	S.	CARISOPRODOL	350MG	120	6616800
9/9/2011	R.	S.	CARISOPRODOL	350 MG	120	6616800
10/22/2011	R.	S.	CARISOPRODOL	350 MG	120	6620033
CVS PHARMACY	<u>(</u>					
12/2/2010	R.	S.	CARISOPRODOL	350 MG	120	193103
1/2/2011	R.	S.	CARISOPRODOL	350 MG	120	193103
2/3/2011	R.	S.	CARISOPRODOL	350 MG	120	193103
2/3/2011	R.	S.	TRAMADOL	50 MG	90	203836
3/5/2011	R.	S.	CARISOPRODOL	350 MG	120	208895
4/6/2011	R.	S.	CARISOPRODOL	350 MG	120	214121
5/4/2011	R.	S.	CARISOPRODOL	350 MG	120	214121
6/7/2011	R.	S.	CARISOPRODOL	350 MG	120	214121
7/5/2011	R.	S.	CARISOPRODOL	350 MG	120	229134
8/6/2011	R.	S.	CARISOPRODOL	350 MG	120	229134
9/3/2011	R.	S.	CARISOPRODOL	350 MG	120	229134
10/8/2011	R.	S.	CARISOPRODOL	350 MG	120	244034
KAISER PHARM	<u>ACY</u>				n a nyaét <u>ari</u> i	, interese and t
9/30/2011	R.	<b>S.</b>	CARISOPRODOL	350 MG	120 45	1678461
11/8/2010	R.	S.	RETIN - A	0.05% CREAM	GMS	1582821
11/26/2010	R.	S.	CARISOPRODOL	350 MG	120	1550337
12/23/2010	Ř.	S.	CARISOPRODOL	350 MG	120	3925719

11057. It is used to treat musculoskeletal pain.

- 11	
1	1/13/2011 R. S. GABAPENTIN 300 MG 200 3931917
$1 \parallel$	1/21/2011 R. S. CARISOPRODOL 350 MG 120 3934321
2	2/27/2011 R. S. CARISOPRODOL 350 MG 120 6228359
3	3/4/2011 R. S. GABAPENTIN 300 MG 200 3948692
	3/21/2011 R. S. CARISOPRODOL 350 MG 120 3957514
4	4/28/2011 R. S. GABAPENTIN 300 MG 200 1634484 4/28/2011 R. S. CARISOPRODOL 350 MG 120 1634486
5	4/28/2011 R. S. CARISOPRODOL 350 MG 120 1634486 5/31/2011 R. S. CARISOPRODOL 350 MG 120 1644782
6	10/10/2011 R. S. GABAPENTIN 300 MG 200 1164203
7	26. Respondent committed gross negligence in his care and treatment of Patient S.R.
8	which included, but was not limited to, the following:
9	(a) Treating Patient S.R., an immediate family member, and, in the course of that
10	treatment, continuously prescribing controlled substances and dangerous drugs, which were
11	highly habit-forming agents, to her.
12	SECOND CAUSE FOR DISCIPLINE (Repeated Negligent Acts)
13	(Repeated Regigent Acts)
14	27. Respondent is further subject to disciplinary action under sections 2227 and 2234, as
15	defined by section 2234, subdivision (c), of the Code, in that he committed repeated negligent
16	acts in his care and treatment of patients M.M. and S.R., as more particularly alleged hereinafter:
17	Paragraphs 11 through 26, above, are hereby incorporated by reference and realleged as if fully
18	set forth herein.
19	THIRD CAUSE FOR DISCIPLINE
20	(Excessive Prescribing)
21	28. Respondent is further subject to disciplinary action under sections 2227, 2234 and
	-
22	725, in that he has excessively prescribed controlled substances and dangerous drugs to M.M., as
23	more particularly alleged hereinafter: Paragraphs 11 through 26, above, are hereby incorporated
24	by reference and realleged as if fully set forth herein.
25	
26	111
27	///

#### FOURTH CAUSE FOR DISCIPLINE

(Prescribing Dangerous Drugs without Appropriate Examination or Medical Indication)

29. Respondent is further subject to disciplinary action under sections 2227 and 2234, as defined by section 2242, of the Code, in that he prescribed controlled substances and dangerous drugs to M.M. without an appropriate medical examination or medical indication, as more particularly alleged hereinafter: Paragraphs 11 through 24, above, are hereby incorporated by reference and realleged as if fully set forth herein.

# FIFTH CAUSE FOR DISCIPLINE (General Unprofessional Conduct)

30. Respondent is further subject to disciplinary action under sections 2227 and 2234, as defined by section 2234, of the Code, in that he has engaged in conduct which breaches the rules or ethical code of the medical profession, or conduct which is unbecoming a member in good standing of the medical profession, and which demonstrates an unfitness to practice medicine, as more particularly alleged hereinafter: Paragraphs 11 through 29, above, are hereby incorporated by reference and realleged as if fully set forth herein.

31. During the period of September 2010 to September 2012, Respondent treated himself and prescribed the following dangerous drugs to himself:

#### TARGET PHARMACY

TANGET TO						
	Lasi	Fires	Drug Name	Strength	Qty	DV#
Date Filled	Name	Name			and the control of the Pelphonese	100 of 10 p. 7 a. o
11/12/2010	R.	G.	CARISOPRODOL	350 MG	120	6609427
12/12/2010	R.	G.	CARISOPRODOL	350 MG	120	6609427
1/15/2011	R.	G.	CARISOPRODOL	350 MG	120	6609427
2/15/2011	R.,	G.	CARISOPRODOL	350 MG	120	6608318
3/18/2011	R.	G.	CARISOPRODOL	350 MG	120	6613098
4/15/2011	R.	G.	CARISOPRODOL	350 MG	120	6613950
5/24/2011	R.	G.	CARISOPRODOL	350 MG	120	6613950
6/27/2011	R.	G.	CARISOPRODOL	350 MG	120	6616208
7/25/2011	R.	G.	CARISOPRODOL	350 MG	120	6616208
8/21/2011	R.	G.	CARISOPRODOL	350 MG	120	6616208
9/15/2011	R.	G.	CARISOPRODOL	350 MG	120	9918648
10/14/2011	R.	G.	CARISOPRODOL	350 MG	120	6618648

,	CVS PHARMACY	,							
1	12/7/2010	R.	G.	CARISOPRODOL	350 MG	120	194142		
2	1/8/2011	R.	G.	CARISOPRODOL	350 MG	120	194142		
2	2/10/2011	R.	G.	CARISOPRODOL	350 MG	120	194142		
3	3/5/2011	R.	G	CARISOPRODOL	350 MG	120	194142		
4	4/6/2011	R.	G,	CARISOPRODOL	350 MG	120	194142		
_	5/4/2011	R.	G.	CARISOPRODOL	350 MG	120	194142		
5	5/5/2011	R.	G.	ZOLPIDEM	10 MG	3	219239		
6	6/7/2011	R.	G.	CARISOPRODOL	350 MG	120	194142		
_	7/5/2011	R.	G.	CARISOPRODOL	350 MG	120	229135		
7	7/31/2011	R.	G.	CARISOPRODOL	350 MG	120	229135		
8	8/27/2011	R.	G.	CARISOPRODOL	350 MG	120	229135		
9	9/24/2011	R.	G.	CARISOPRODOL	350 MG	120	241767		
10	KAISER PHARM	<u>ACY</u>			and the messes be seen to the transfer of the	DAJSS SAUSSE BOOKHAN NIPH II DOGG DEGE			
						80	000000		
11	12/13/2010	R.	G.	DIOVAN	160 MG	TABS 60	3922653		
12	12/13/2010	R.	G.	ADVAIR	100/50 DISKUS	EACH	3922666		
•	12/13/2010	n.	G.	ADVAIN	100/30 DI3K03	8.5	3522000		
13	12/13/2010	R.	G.	ALBUTEROL	90 MCG	MGS	3922678		
14	12/23/2010	R.	G.	CRESTOR	20 MG	90	3922665		
						8.5			
15	2/11/2011	R.	G.	ALBUTEROL	90 MCG	GMS	3941804		
16	2/18/2011	R.	G.	DIOVAN	160 MG	80	3941802		
	1/20/2004	Б		ALBUTEDO!	90 MCG	8.5 GMS	1634482		
17	4/28/2011	R.	G.	ALBUTEROL DIOVAN	160 MG	200	1634472		
18	4/29/2011	R.	G. G.	CRESTOR	20 MG	90	164478		
	6/23/2011 9/14/2011	R. R.	G.	CLONIDINE	0.1 MG	180	1673660		
19	9/15/2011		G.	DIOVAN	160 MG	180	1674190		
20	3/13/2011	::11		Dio, vivil and the second		— <del></del>			
21	32. Res	pone	dent engaged i	n unprofessional c	onduct in that he prescri	ibed dange	rous drugs		
22	to himself.								
23			SIX	TH CAUSE FOR	RDISCIPLINE				
23	(E. House to Maintain Adaquete and Accurate Medical Records)								

## (Failure to Maintain Adequate and Accurate Medical Records)

Respondent is further subject to discipline under sections 2227 and 2234, as defined 33. by section 2266, of the Code, in that he failed to maintain adequate and accurate medical records in the care and treatment of patient M.M. and himself, as more particularly alleged hereinafter.

24

25

26

27

1	Paragraphs 11 through 32, above, are hereby incorporated by reference and realleged as if fully
2	set forth herein.
3	PRAYER
4	WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
5	and that following the hearing, the Medical Board of California issue a decision:
6	1. Revoking or suspending Physician's and Surgeon's Certificate Number G 67994,
7	issued to Respondent Gary Scott Rinzler, M.D.
8	2. Revoking, suspending or denying approval of Respondent Gary Scott Rinzler, M.D.'s
9	authority to supervise physician assistants, pursuant to section 3527 of the Code;
10	3. If Respondent Gary Scott Rinzler, M.D., is placed on probation, ordering him to pay
11	the Medical Board of California the costs of probation monitoring; and
12	4. Taking such other and further action as deemed necessary and proper.
13	O(11)
14	DATED: August 27, 2013  KIMBERI Y KIRCHMEYER
15	Interim Executive Director  Medical Board of California
16	State of California
17	Complainant
18	SA2013308474
19	31758418.doc
20	
21	
22	
23	
24	
25	
26 27	
28	
∠ŏ	